Business brief
Tech Exports and Retail Trading Drive Israeli Corporate Growth
Nvidia's Yokneam operations distort national GDP figures, Wix subsidiary Base44 doubles AI recurring revenue, and IBI posts record Q2 profits.
Business
Global AI infrastructure spending routed through Nvidia's Yokneam hub is now large enough to single-handedly distort Israel's national growth statistics.
BackgroundNvidia acquired Israeli networking pioneer Mellanox in 2020, transforming Yokneam into its hub for AI data center interconnects. Because export intellectual property is recorded locally while hardware assembly occurs overseas, sudden revenue spikes trigger disproportionate swings in official growth metrics.
- Surging global demand for Mellanox InfiniBand networking hardware pushed overall Q2 annualized economic expansion to 15.4%, up dramatically from initial domestic forecasts.
- The Central Bureau of Statistics released an adjusted metric excluding local intellectual property transfers, which showed underlying domestic GDP growth was a lower 14.4%.
- The data distortion highlights how a single multinational hub can obscure real domestic economic trends, complicating Central Bank interest rate decisions.
Business
Base44's $200M revenue run-rate proves corporate subscribers will pay premium recurring software prices for high-end AI automation.
BackgroundIsraeli web creation leader Wix acquired Base44 in 2025 to power enterprise-grade automated web building systems driven by custom generative design engines. Rapid commercial adoption among enterprise clients has dramatically accelerated the subsidiary's valuation payouts.
- Base44 doubled its annual recurring revenue from $100 million in March to $200 million following the deployment of its enterprise AI workflow system.
- Wix confirmed in financial disclosures that total acquisition proceeds to founder Maor Shlomo will exceed $150 million based on milestone achievements.
- The subscriber jump shows that corporate customers are willing to pay premium recurring rates for AI tools that replace manual web development.
Business
UroGen is using structured milestone options to lock up IntraGel's localized cancer platform without taking on immediate full-acquisition liabilities.
BackgroundSpecialty hydrogel delivery platforms release chemotherapy agents slowly inside localized tumor sites, minimizing systemic toxicity for cancer patients. UroGen focuses on polymer-based hydrogel treatments for urological cancers, while IntraGel develops sustained-release platforms for head and neck oncology.
- UroGen will provide $4 million in upfront capital to fund Phase 2 trials for IntraGel's lead TumoCure candidate, ensuring pipeline development continues.
- The agreement grants UroGen an exclusive worldwide option to acquire TumoCure outright following successful completion of Phase 2 clinical trials.
- UroGen also secured licensing options for IntraGel's proprietary SRGel delivery platform across three additional oncology drug candidates, expanding its future deal architecture.
Business
Surging local retail trading and corporate debt servicing are generating record profits for Tel Aviv financial institutions.
BackgroundDomestic investment houses in Israel benefit directly from expanded local retail trading volumes and high-tech corporate debt management. IBI operates retail brokerage, institutional asset management, and high-tech corporate trust services across Tel Aviv financial markets.
- Private trading platform revenue jumped 25% year-over-year to ₪99 million, which drove a 147% surge in retail segment operating profit.
- IBI's high-tech business segment nearly quintupled profits as local tech firms increasingly used its corporate trust and debt management services.
- Total assets under management and trust across IBI's financial service divisions reached approximately ₪95 billion during the second quarter.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
